Cogstate Toekomstige groei

Future criteriumcontroles 2/6

Cogstate zal naar verwachting groeien in winst en omzet met respectievelijk 6.6% en 10.9% per jaar. De winst per aandeel zal naar verwachting groeien met 5.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 12% zijn.

Belangrijke informatie

6.6%

Groei van de winst

5.1%

Groei van de winst per aandeel

Healthcare Services winstgroei	20.8%
Inkomstengroei	10.9%
Toekomstig rendement op eigen vermogen	12.0%
Dekking van analisten	Low
Laatst bijgewerkt	22 Aug 2024

Recente toekomstige groei-updates

Recent updates

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Aug 30

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

Jul 26

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Mar 23

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

Mar 02

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Jan 13

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Oct 04

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Sep 28

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Sep 02

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Jun 30

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

Mar 22

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Oct 20

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Jul 23

Is Cogstate (ASX:CGS) Using Too Much Debt?

Apr 29

What Can The Trends At Cogstate (ASX:CGS) Tell Us About Their Returns?

Mar 14

Here's What Cogstate Limited's (ASX:CGS) Shareholder Ownership Structure Looks Like

Feb 21

How Much Is Cogstate's (ASX:CGS) CEO Getting Paid?

Jan 17

Can You Imagine How Jubilant Cogstate's (ASX:CGS) Shareholders Feel About Its 214% Share Price Gain?

Dec 05

Winst- en omzetgroeiprognoses

ASX:CGS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2026	54	6	9	9	1
6/30/2025	47	5	5	6	1
6/30/2024	43	5	4	6	N/A
3/31/2024	42	5	1	3	N/A
12/31/2023	41	6	-1	0	N/A
9/30/2023	41	5	-1	1	N/A
6/30/2023	40	4	-2	1	N/A
3/31/2023	41	4	1	4	N/A
12/31/2022	41	3	4	8	N/A
9/30/2022	43	6	5	9	N/A
6/30/2022	45	8	6	10	N/A
3/31/2022	43	9	4	7	N/A
12/31/2021	42	10	2	4	N/A
9/30/2021	37	7	8	10	N/A
6/30/2021	33	5	13	16	N/A
3/31/2021	30	3	12	16	N/A
12/31/2020	28	0	11	15	N/A
9/30/2020	25	-1	4	8	N/A
6/30/2020	23	-2	-2	1	N/A
3/31/2020	21	-3	-3	0	N/A
12/31/2019	19	-3	-4	-2	N/A
9/30/2019	21	-3	-3	-1	N/A
6/30/2019	22	-2	-3	0	N/A
3/31/2019	24	-2	-2	1	N/A
12/31/2018	27	-1	-1	2	N/A
9/30/2018	28	-1	-2	1	N/A
6/30/2018	29	-1	-3	0	N/A
3/31/2018	27	-2	N/A	-1	N/A
12/31/2017	26	-3	N/A	-2	N/A
9/30/2017	26	-2	N/A	0	N/A
6/30/2017	26	-1	N/A	2	N/A
3/31/2017	26	0	N/A	3	N/A
12/31/2016	24	1	N/A	4	N/A
9/30/2016	23	1	N/A	3	N/A
6/30/2016	20	2	N/A	2	N/A
3/31/2016	19	1	N/A	1	N/A
12/31/2015	17	0	N/A	-1	N/A
9/30/2015	14	-2	N/A	-1	N/A
6/30/2015	12	-4	N/A	-2	N/A
3/31/2015	11	-3	N/A	-2	N/A
12/31/2014	10	-3	N/A	-2	N/A
9/30/2014	10	-3	N/A	-3	N/A
6/30/2014	11	-4	N/A	-3	N/A
3/31/2014	11	-4	N/A	-3	N/A
12/31/2013	11	-4	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CGS ( 6.6% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van CGS ( 6.6% per jaar) zal naar verwachting langzamer groeien dan de markt Australian ( 12.5% per jaar).

Hoge groeiwinsten: De winst van CGS zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van CGS ( 10.9% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.7% per jaar).

Hoge groei-inkomsten: De omzet van CGS ( 10.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CGS zal naar verwachting over 3 jaar laag zijn ( 12 %).

Cogstate Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

Price target decreased by 8.1% to AU$1.70

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Price target decreased by 9.0% to AU$1.70

Recent updates

Cogstate Appoints Kaycee Sink as Chief Medical Officer

CEO, MD & Executive Director exercised options to buy AU$965k worth of stock.

New minor risk - Market cap size

Pinning Down Cogstate Limited's (ASX:CGS) P/E Is Difficult Right Now

Non-Executive Chairman recently bought AU$108k worth of stock

Full year 2024 earnings: EPS exceeds analyst expectations

Cogstate Limited Provides Financial Guidance for the Fiscal Year 2025

Consensus revenue estimates decrease by 10%, EPS upgraded

There's Been No Shortage Of Growth Recently For Cogstate's (ASX:CGS) Returns On Capital

If EPS Growth Is Important To You, Cogstate (ASX:CGS) Presents An Opportunity

First half 2024 earnings released: EPS: US$0.012 (vs US$0 in 1H 2023)

Price target decreased by 8.1% to AU$1.70

Investor sentiment deteriorates as stock falls 17%

The Price Is Right For Cogstate Limited (ASX:CGS)

Cogstate Limited to Report First Half, 2024 Results on Feb 22, 2024

Price target increased by 8.6% to AU$1.85

Cogstate Limited Provides Revenue Guidance for 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Is Cogstate Limited (ASX:CGS) Trading At A 29% Discount?

Now 21% undervalued

Price target decreased by 9.0% to AU$1.70

Now 23% undervalued

Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023

Consensus EPS estimates increase by 12%

Returns Are Gaining Momentum At Cogstate (ASX:CGS)

Growth Investors: Industry Analysts Just Upgraded Their Cogstate Limited (ASX:CGS) Revenue Forecasts By 11%

Consensus revenue estimates increase by 11%

Investor sentiment deteriorates as stock falls 16%

CEO, MD & Executive Director recently bought AU$100k worth of stock

Earnings Update: Cogstate Limited (ASX:CGS) Just Reported And Analysts Are Trimming Their Forecasts

First half 2023 earnings released: EPS: US$0 (vs US$0.024 in 1H 2022)

Consensus EPS estimates increase by 23%, revenue downgraded

Investor sentiment deteriorates as stock falls 25%

Now 24% undervalued

Cogstate Limited to Report Fiscal Year 2023 Results on Aug 17, 2023

Now 22% undervalued

Cogstate Limited Announces Resignation of David Dolby as Non-Executive Director

Cogstate Limited (ASX:CGS) Shares Could Be 19% Below Their Intrinsic Value Estimate

Price target decreased to AU$1.92

High number of new and inexperienced directors

Investors Appear Satisfied With Cogstate Limited's (ASX:CGS) Prospects As Shares Rocket 51%

Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Returns On Capital Are A Standout For Cogstate (ASX:CGS)

Price target decreased to AU$2.18

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$2.41

Cogstate Limited Provides Earnings Guidance for the Fiscal Year 2023

High number of new and inexperienced directors

Price target decreased to AU$2.43

Investor sentiment improved over the past week

High number of new and inexperienced directors

We Ran A Stock Scan For Earnings Growth And Cogstate (ASX:CGS) Passed With Ease

Cogstate Announces Formation of Scientific Advisory Board

Consensus EPS estimates fall by 82%

Investor sentiment improved over the past week

Investors Should Be Encouraged By Cogstate's (ASX:CGS) Returns On Capital

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

We Think Some Shareholders May Hesitate To Increase Cogstate Limited's (ASX:CGS) CEO Compensation

Independent Non-Executive Director exercised options to buy AU$244k worth of stock.

Non-Executive Chairman recently sold AU$89k worth of stock

Non-Executive Chairman exercised options and sold AU$188k worth of stock

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS US$0.031 (vs US$0.008 loss in FY 2020)

Insider recently sold AU$1.8m worth of stock

Cogstate (ASX:CGS) Is Looking To Continue Growing Its Returns On Capital

Insider recently sold AU$1.3m worth of stock